{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:05:36Z","timestamp":1791515136377,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1124\/dmd.119.086918","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T14:19:09Z","timestamp":1568125149000},"page":"1291-1306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban"],"prefix":"10.1016","volume":"47","author":[{"given":"Eleanor Jing Yi","family":"Cheong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Wun Xi","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Xin Yi","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9072","authenticated-orcid":false,"given":"Eric Chun Yong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.086918_bib1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1124\/dmd.114.058099","article-title":"Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations","volume":"42","author":"Abduljalil","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/dmd.107.017301","article-title":"Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells","volume":"36","author":"Acharya","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib3","doi-asserted-by":"crossref","first-page":"31422","DOI":"10.1074\/jbc.M109.024489","article-title":"Interaction of organic cations with organic anion transporters","volume":"284","author":"Ahn","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.119.086918_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(69)90053-9","article-title":"On the meaning of the intact nephron hypothesis","volume":"46","author":"Bricker","year":"1969","journal-title":"Am J Med"},{"key":"10.1124\/dmd.119.086918_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2016.03.020","article-title":"Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions","volume":"88","author":"Burt","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.119.086918_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1124\/dmd.119.086918_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am J Nephrol"},{"issue":"Suppl 7","key":"10.1124\/dmd.119.086918_bib8","first-page":"S132","article-title":"More power to OATP1B1: an evaluation of sample size in pharmacogenetic studies using a rosuvastatin PBPK model for intestinal, hepatic, and renal transporter-mediated clearances","volume":"56","author":"Emami Riedmaier","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/psp4.12056","article-title":"A model qualification method for mechanistic physiological QSP models to support model-informed drug development","volume":"5","author":"Friedrich","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/j.1552-4604.1992.tb03862.x","article-title":"Sustained-release verapamil formulations for treating hypertension","volume":"32","author":"Frishman","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib11","series-title":"Pharmacokinetic Profiling in Drug Research","first-page":"259","article-title":"Predicting the intestinal solubility of poorly soluble drugs","author":"Glomme","year":"2007"},{"key":"10.1124\/dmd.119.086918_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086918_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jcph.1040","article-title":"Impaired rivaroxaban clearance in mild renal insufficiency with verapamil coadministration: potential implications for bleeding risk and dose selection","volume":"58","author":"Greenblatt","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/bdd.1771","article-title":"Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice","volume":"33","author":"Grillo","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.119.086918_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib16","first-page":"383","article-title":"Metabolite parameters as an appropriate alternative approach for assessment of bioequivalence of two verapamil formulations","volume":"13","author":"Haeri","year":"2014","journal-title":"Iran J Pharm Res"},{"key":"10.1124\/dmd.119.086918_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-013-0117-y","article-title":"Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations","volume":"53","author":"Hsu","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.086918_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/cpt.750","article-title":"PBPK modeling of the effect of reduced kidney function on the pharmacokinetics of drugs excreted renally by organic anion transporters","volume":"103","author":"Hsueh","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib19","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1021\/acs.molpharmaceut.6b00332","article-title":"Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3","volume":"13","author":"Hsueh","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.119.086918_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/psp4.12321","article-title":"Development of a dynamic physiologically based mechanistic kidney model to predict renal clearance","volume":"7","author":"Huang","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jcph.1044","article-title":"Minimal physiologically based pharmacokinetic and drug-drug-disease interaction model of rivaroxaban and verapamil in healthy and renally impaired subjects","volume":"58","author":"Ismail","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"10.1124\/dmd.119.086918_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.119.086918_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol (2014) 64:2305\u20132307]","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/dmd.119.086918_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1124\/dmd.119.086918_bib56","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib27","doi-asserted-by":"crossref","first-page":"e69394","DOI":"10.1371\/journal.pone.0069394","article-title":"Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp","volume":"8","author":"Lumen","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.119.086918_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.187112","article-title":"Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model","volume":"341","author":"M\u00e9nochet","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086918_bib29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jcph.352","article-title":"An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function","volume":"54","author":"Moore","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.086918_bib32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1124\/dmd.111.039115","article-title":"Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats","volume":"39","author":"Naud","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cpt.593","article-title":"Scalpels not hammers: the way forward for precision drug prescription","volume":"101","author":"Neely","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib34","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.119.086918_bib35","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1124\/dmd.116.072066","article-title":"Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics","volume":"44","author":"Prasad","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1124\/dmd.119.086918_bib57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/dmd.112.048264","article-title":"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors","volume":"41","author":"Ren","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib36","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.119.086918_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cpt.904","article-title":"Reverse translation in PBPK and QSP: going backwards in order to go forward with confidence","volume":"103","author":"Rostami-Hodjegan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib38","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","article-title":"New oral anticoagulants: comparative pharmacology with vitamin K antagonists","volume":"52","author":"Scaglione","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.119.086918_bib40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/jpet.116.237438","article-title":"Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations","volume":"360","author":"Scotcher","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.086918_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/cpt.689","article-title":"Physiologically based pharmacokinetic modeling suggests limited drug-drug interaction between clopidogrel and dasabuvir","volume":"102","author":"Shebley","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.086918_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jpba.2013.05.011","article-title":"Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid","volume":"83","author":"Tak\u00e1cs-Nov\u00e1k","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.119.086918_bib45","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.xphs.2017.04.044","article-title":"Different involvement of OAT in renal disposition of oral anticoagulants rivaroxaban, dabigatran, and apixaban","volume":"106","author":"Tsuruya","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.119.086918_bib46","unstructured":"US Food and Drug Aministration (2011a) XARELTO (rivaroxaban), Clinical Pharmacology and Biopharmaceutics Review, U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"10.1124\/dmd.119.086918_bib47","unstructured":"US Food and Drug Aministration (2011b) XARELTO (rivaroxaban) product information, U.S. Food and Drug Administration, Silver Spring, MD."},{"key":"10.1124\/dmd.119.086918_bib48","unstructured":"US Food and Drug Aministration (2017) Drug development and drug interactions: table of substrates, inhibitors and inducers, Center for Drug Evaluation and Research, Silver Spring, MD."},{"key":"10.1124\/dmd.119.086918_bib49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.086918_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/js980236p","article-title":"General solution for diffusion-controlled dissolution of spherical particles. 1. Theory","volume":"88","author":"Wang","year":"1999","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.119.086918_bib51","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-glycoprotein transport system and cardiovascular drugs [published correction appears in J Am Coll Cardiol (2014) 63:2176]","volume":"61","author":"Wessler","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/dmd.119.086918_bib52","series-title":"Handbook of Pharmaceutical Controlled Release Technology","author":"Wise","year":"2000"},{"key":"10.1124\/dmd.119.086918_bib53","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00228-018-2430-8","article-title":"Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban","volume":"74","author":"Xu","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.086918_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.2009.03390.x","article-title":"Safety, pharmacokinetics and pharmacodynamics of single\/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects","volume":"68","author":"Zhao","year":"2009","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.086918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:23:20Z","timestamp":1739957000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624077912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0090955624077912"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.086918","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.086918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}